Physician profile
James Wang
NPI 1801890884
$3,746.00
in general payments reported to CMS, 2019-2025
31 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $331 · 2021: $269 · 2022: $355 · 2023: $484 · 2024: $538 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $668.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $609.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $431.41 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $395.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $287.06 | 2019-2024 | Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $178.70 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Glaxosmithkline, LLC. | $123.87 | 2019-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.86 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $80.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.85 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $72.85 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $67.84 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $61.40 | 2019-2020 | |
| Abbott Laboratories | $57.27 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Astellas Pharma US INC | $54.22 | 2019-2023 | Myrbetriq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $54.07 | 2019-2022 | |
| Allergan, INC. | $46.83 | 2019-2020 | |
| Amgen INC. | $44.22 | 2020-2025 | Evenity, Prolia |
| Janssen Biotech, INC. | $39.95 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $38.65 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $35.06 | 2019-2021 | |
| Ardelyx, INC. | $31.91 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.41 | 2019 | |
| Boston Scientific Corporation | $25.73 | 2024 | Wavewriter Alpha Prime 16 |
| Baxter Healthcare | $23.50 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $18.24 | 2024 | Intellis Adaptivestim |
| Paratek Pharmaceuticals, INC. | $16.15 | 2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $15.70 | 2022 | |
| G Medical Diagnostic Services, INC. | $14.13 | 2022 | |
| Nevro Corp. | $12.31 | 2022 | |
| Zyla Life Sciences, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.